Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug5267 | this study is non- interventional Wiki | 1.00 |
Name (Synonyms) | Correlation | |
---|---|---|
D003922 | Diabetes Mellitus, Type 1 NIH | 0.28 |
D003920 | Diabetes Mellitus, NIH | 0.16 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0100651 | Type I diabetes mellitus HPO | 0.28 |
HP:0000819 | Diabetes mellitus HPO | 0.16 |
Navigate: Correlations HPO
There is one clinical trial.
This study will evaluate (1) the efficacy of REAL-T, a lifestyle-based telehealth intervention, in improving glycemic control (HbA1c) and psychosocial outcomes, (2) which effects are retained over a 6-month follow-up period, and (3) the mediating mechanisms responsible for the intervention's effects. Half of participants will receive REAL-T, while the other half will receive their usual care.
Description: HbA1C is a measure of average blood glucose concentration over approximately the previous 12 weeks. HbA1C will be measured using a finger-prick test and DCA Vantage Analyzer point-of-care system.
Measure: Change in glycemic control, using Glycated Hemoglobin (HbA1C) Time: Baseline, 3 months, 6 months, 9 months, and 12 monthsDescription: 15-item questionnaire assessing diabetes-related quality of life (qol). Each item contains two parts. Part A is: "If I did not have diabetes, [the question topic] would be", followed by 5 options ranging from "very much better" (or similar; scored as -3) to "worse" (or similar; scored as 1). The fourth option is always "the same" and scored as 0. Part B is: "[the question topic] is" followed by 4 options ranging from "very important" (scored as 3) to "not at all important" (scored as 0). For each question, scores on parts A and B are multiplied, and the 15 products are summed for a total score. Questions 2, 4, 6, 8, 9, & 11 have preliminary yes/no questions, and when a "no" response is given, parts A and B are skipped and the score for that question is 0. The minimum score on each question is -9 and the maximum is 3, with total scores ranging from -135 to 45. Positive scores reflect perceived positive impact of diabetes on qol; negative scores reflect perceived negative impact on qol.
Measure: Change in diabetes-related quality of life, using the "Audit of Diabetes-Dependent Quality of Life-15" (ADD-QoL-15) Time: Baseline, 6 months, and 12 monthsDescription: 17-item questionnaire assessing diabetes-related emotional distress. Total scores (mean score on all 17 items) range from 1 to 6. Sub-scale scores (emotional burden, physician-related distress, regimen-related distress, and interpersonal distress) each range from 1 to 6. A total or sub-scale score 2.0 - 2.9 should be considered 'moderate distress,' and a total or sub-scale score > 3.0 should be considered 'high distress.'
Measure: Change in diabetes-related emotional distress, using the "Diabetes Distress Scale" (DDS) Time: Baseline, 6 months, and 12 monthsDescription: Short Form 12-item Health Survey Ver. 2 (SF-12v2) is a 12-item questionnaire assessing functional health & well-being over the last 4 weeks in 8 health domains (physical functioning, role participation with physical health problems, bodily pain, general health, vitality, social functioning, role participation with emotional health problems, mental health), all from the patient's point of view. These 8 domains can be summarized into a physical component summary (PCS) and a mental component summary (MCS). Higher scores indicate a better health state. MCS and PCS scores range from 0-100. Scores are calibrated using general population-derived normative data so that 50 is the avg score or norm. Results can be further summarized into a single preference-based health utility number ranging from 1 (equivalent to perfect health) to 0 (equivalent to being dead), using a complex scoring algorithm (SF-6D) derived from surveying a general U.S. population's preferences for specific health states.
Measure: Change in functional health and well-being, using the "SF-12v2® Health Survey" Time: Baseline, 6 months, and 12 monthsDescription: 27-item questionnaire assessing self-care activities associated with glycemic control. Higher values indicate more effective self-management. Transformed scores = Actual sum of items / maximum possible sum of items x 10. Total transformed scores range from 0 to 10. Transformed scores on six sub-scales (Dietary control, Glucose management, Glucose monitoring, Medication adherence, Physical activity, and Physician contact) also range from 0 to 10.
Measure: Change in global diabetes self-management, using the "Diabetes Self-Management Questionnaire-Revised" (DSMQ-R). Time: Baseline, 3 months, 6 months, 9 months, and 12 monthsDescription: 3-item questionnaire (Wilson,Lee, Fowler, & Rogers, 2016) assessing adherence to diabetes medication regimen. Item responses for the three adherence items are linearly transformed to a 0-100 scale with zero being the worst adherence, and 100 the best. A total summary score is calculated as the mean of the three individual items, with a range of 0 to 100.
Measure: Change in medication adherence, using the "3-item adherence self-report scale" questionnaire Time: Baseline, 3 months, 6 months, 9 months, and 12 monthsDescription: 4-item questionnaire assessing habit strength for testing blood sugar, using 7-point likert scales. Scores range from 4 to 28. A higher score indicates greater automaticity.
Measure: Change in automaticity of behavior (testing blood sugar), using the "Self-Report Behavioural Automaticity Index" (SRBAI) Time: Baseline, 3 months, 6 months, 9 months, and 12 monthsDescription: 8-item questionnaire assessing self-efficacy for performing diabetes self-management, using 5-point likert scales. The scale is scored by averaging the scores of all completed items. Scores range from 8 to 40, with higher scores indicating higher self-efficacy.
Measure: Change in self-efficacy for performing diabetes self-management, using the "Diabetes Empowerment Scale - Short Form" (DES-SF) Time: Baseline, 3 months, 6 months, 9 months, and 12 monthsDescription: 19-item questionnaire, adapted for type 1 diabetes, assessing the degree to which a person's motivation for a particular behavior or a set of behaviors is relatively autonomous or self-determined. Each item can receive a value ranging from 1 - 7 as selected by the participant. The scale has 2 sub-scales: the autonomous regulatory style and the controlled regulatory style. Calculating the scores for the sub-scales consists of averaging the items on that sub-scale. A Relative Autonomous Motivation Index can be formed by subtracting the average for the controlled reasons from the average for the autonomous reasons. Scores range from 1 to 7, with 7 indicating a strong identification with the given autonomy style. The autonomous regulatory style represents the most self-determined form of motivation.
Measure: Change in autonomy of taking insulin and/or checking blood sugar, using the "Treatment Self-Regulation Questionnaire" (TSRQ) Time: Baseline, 3 months, 6 months, 9 months, and 12 monthsDescription: 9 diabetes-related expense questions designed by the study (polar questions, multiple choice, and open-ended). Questions assess loss of income or other productivity due to diabetes (3 items), and impact of cost and health insurance on access to and use of insulin and test strips (6 items).
Measure: Change in cost to patients Time: Baseline, 3 months, 6 months, 9 months, and 12 monthsDescription: The number of blood glucose checks over the 14 days prior to each assessment session will be recorded through download of participants' meter data or, if incompatible, through manual review of blood glucose checks recorded on the participant's meter.
Measure: Change in self management of blood glucose, using the # of blood glucose checks Time: Baseline, 3 months, 6 months, 9 months, and 12 monthsDescription: The proportion of time when blood glucose was between 70 and 180 mg/dl, as measured by an Abbott FreeStyle Libre Pro continuous glucose monitor worn on the arm for 14 days.
Measure: Change in glycemic control, using Percent Time-in-Range Time: Baseline, 6 months, and 12 monthsDescription: The proportion of time when blood glucose was above 180 mg/dl, as measured by an Abbott FreeStyle Libre Pro continuous glucose monitor worn on the arm for 14 days.
Measure: Change in glycemic control, using Percent Time in Hyperglycemia Time: Baseline, 6 months, and 12 monthsDescription: The proportion of time when blood glucose was below 70 mg/dl, as measured by an Abbott FreeStyle Libre Pro continuous glucose monitor worn on the arm for 14 days.
Measure: Change in glycemic control, using Percent Time in Hypoglycemia Time: Baseline, 6 months, and 12 monthsDescription: 18-item questionnaire assessing intervention participants' satisfaction with the study's telehealth procedures. Scores on items 4-14 (likert-scaled items) range from 1 to 5, with 5 indicating higher satisfaction. Total score is calculated by averaging items 4-14. The remaining 7 items are Yes/No, Yes/No/Maybe, and open-ended items used to characterize the population descriptively and indicate willingness to use/recommend telehealth in the future. These additional 7 items are not used in any scoring calculations.
Measure: Telehealth Satisfaction Time: 6 monthsDescription: 8-item healthcare utilization questionnaire designed by the study. Polar; Yes/No questions about health service usage in the last month: (e.g., "have you had to be admitted to the hospital?"). Open-ended questions about number of time health services were used, (e.g., "how many times were you admitted to the hospital for reasons related to diabetes?").
Measure: Change in cost to payor Time: Baseline, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, and 12 monthsDescription: 19-item questionnaire, designed by the study, gathering background data on demographic characteristics and baseline healthcare utilization (for prior 3 months). No total score will be calculated. Scores on individual items will be used as covariates in various analyses.
Measure: Background Information Time: BaselineAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports